2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1425

Validation of a Patient Reported Experience Measure (PREM) in Patients with Axial Spondyloarthropathies (AxSpA)
Abstract Number: 1692

Validation of a Two-Question Patient Reported Outcome Measure for Psoriasis
Abstract Number: 2385

Validation of Diary Score for the Assessment of Disease Activity in Candle (Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) and SAVI (STING associated vasculopathy with onset in Infancy) Patients
Abstract Number: 1665

Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease
Abstract Number: 553

Validation of Index of Activity Speed (Timed Up and Go test) for Outcome Measure of Patients with Long-Standing Rheumatoid Arthritis: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function
Abstract Number: 1420

Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus
Abstract Number: 3159

Validation of MRI Structural Lesions Using Computed Tomography in Patients with Axial Spondyloarthritis
Abstract Number: 2003

Validation of the ASAS Health Index: Results of a Multicenter International Study in 23 Countries
Abstract Number: 1412

Validation of the Danish Version of the Stanford Health Assessment Questionnaire Disability Index and Determination of the Minimal Clinically Important Difference in a Cohort of Rheumatoid Arthritis Patients Using the Rasch Measurement Model
Abstract Number: 2167

Validation of the Earp Questionnaire: Detection of Psoriatic Arthritis in the Spanish Population
Abstract Number: 2467

Validation of the FLARE Questionnaire for the Detection of a Disease Flare in Rheumatoid Arthritis
Abstract Number: 1419

Validation of the French Version of Lupus Patient Reported Outcome (LupusPRO), a Disease-Specific Patient Reported Outcome for Lupus Patients
Abstract Number: 994

Validation Studies of the American College of Rheumatology (ACR) 2010 Fibromyalgia Diagnostic Criteria and the 2011 Self-Report Modification for Survey and Clinical Research
Abstract Number: 2041

Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form in Patients with SLE
Abstract Number: 3016

Validity of a 2-Component Disease Activity Score for Accurate Assessment of Synovitis in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].